Abhishek Tyagi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Abhishek Tyagi has a total of 174 co-authors. Here are the top co-authors by number of shared publications:
Kerui Wu
Department of Cancer Biology, Wake Forest Baptist Medical Center, Winston-Salem, USA
25 shared publicationsShih-Ying Wu
Department of Cancer Biology, Wake Forest Baptist Medical Center , Winston-Salem, North Carolina
25 shared publications- Kounosuke Watabe
Department of Cancer Biology, Wake Forest Baptist Medical Center , Winston-Salem, North Carolina
24 shared publications Sambad Sharma
Department of Cancer Biology, Wake Forest Baptist Medical Center, Winston-Salem, USA
21 shared publications- Dan Zhao
Section of Epidemiology and Population Sciences, Department of Medicine Baylor College of Medicine Houston Texas USA
19 shared publications Yin Liu
Department of Cancer Biology, Wake Forest Baptist Medical Center, Winston-Salem, USA
16 shared publications
Latest Publications
- Open Access
- 26 August 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
GABA shunt metabolism drives smoking-related peri-neuronal brain metastasis by hijacking synaptic signaling
Background: Brain metastases are a major clinical challenge with poor prognosis, particularly in patients with a history of smoking. While neurons are abundant in the brain and capable of synaptic interaction with tumor cells, their role in brain metastasis remains poorly understood. Emerging evidence suggests that neuronal activity may contribute to metastatic progression, yet the mechanisms by which smoking alters the brain microenvironment to promote tumor growth are unclear. Methods: We examined the impact of nicotine exposure on microglia-neuron-tumor interactions in brain metastasis models using in vivo and ex vivo approaches. We analyzed patient-derived brain metastatic tissues, performed molecular and metabolic profiling, and utilized pharmacologic inhibition strategies to dissect the underlying mechanisms of tumor-neuron communication. Results: Our findings reveal a significant association between smoking history and perineural invasion in brain metastases. Nicotine exposure stimulates microglia to release exosomal miR-32-3p, which activates GABAergic neurons and enhances gamma-aminobutyric acid (GABA) release. GABA acts as a metabolic substrate in the tumor microenvironment, fueling tumor growth through the GABA shunt pathway. Pharmacological inhibition of GABA uptake with FDA-approved GABA transporter (GAT) inhibitors Tiagabine and NO-711 significantly suppress brain metastatic progression in vivo. Conclusions: This study identifies a novel GABAergic neuron-microglia-tumor signaling axis by which smoking promotes brain metastasis via GABAergic metabolic reprogramming. Targeting GABA uptake on tumor cells using repurposed anticonvulsant drugs offers a promising therapeutic strategy, particularly for patients with smoking-associated brain metastases.
- 26 August 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
Open AccessGABA shunt metabolism drives smoking-related peri-neuronal brain metastasis by hijacking synaptic signaling
Background: Brain metastases are a major clinical challenge with poor prognosis, particularly in patients with a history of smoking. While neurons are abundant in the brain and capable of synaptic interaction with tumor cells, their role in brain metastasis remains poorly understood. Emerging evidence suggests that neuronal activity may contribute to metastatic progression, yet the mechanisms by which smoking alters the brain microenvironment to promote tumor growth are unclear. Methods: We examined the impact of nicotine exposure on microglia-neuron-tumor interactions in brain metastasis models using in vivo and ex vivo approaches. We analyzed patient-derived brain metastatic tissues, performed molecular and metabolic profiling, and utilized pharmacologic inhibition strategies to dissect the underlying mechanisms of tumor-neuron communication. Results: Our findings reveal a significant association between smoking history and perineural invasion in brain metastases. Nicotine exposure stimulates microglia to release exosomal miR-32-3p, which activates GABAergic neurons and enhances gamma-aminobutyric acid (GABA) release. GABA acts as a metabolic substrate in the tumor microenvironment, fueling tumor growth through the GABA shunt pathway. Pharmacological inhibition of GABA uptake with FDA-approved GABA transporter (GAT) inhibitors Tiagabine and NO-711 significantly suppress brain metastatic progression in vivo. Conclusions: This study identifies a novel GABAergic neuron-microglia-tumor signaling axis by which smoking promotes brain metastasis via GABAergic metabolic reprogramming. Targeting GABA uptake on tumor cells using repurposed anticonvulsant drugs offers a promising therapeutic strategy, particularly for patients with smoking-associated brain metastases.
- 2 March 2026
- Published by Springer Nature in Nature Biomedical Engineering
- p. 1-19
MyD88-mediated chimaeric antigen receptor macrophages suppress brain metastasis using target-specific phagocytosis
Metastatic brain disease occurs in up to 30% of patients with lung, melanoma and breast cancers, and the median survival time remains less than a year. Treating these patients is a challenge because surgical approaches are limited and most chemotherapeutic drugs and immunotherapies are ineffective at crossing the blood–brain barrier (BBB). Given the unique abilities of macrophages to cross the BBB and exert their phagocytic function on tumour cells, we genetically engineer macrophages that express a chimaeric antigen receptor (CAR) targeting mesothelin (MSLN). To specifically target metastatic brain tumours, we fused the cells with the immune signalling molecule MyD88. This chimaeric antigen receptor macrophage (CARMA) penetrates the BBB and decreases brain metastasis growth in a humanized mouse model. MSLN–CARMA shows antigen-specific phagocytosis activity against tumour cells and exhibits a bystander effect by releasing TNF to act on surrounding tumour cells lacking the tumour antigen. These features of CARMA represent advantages over other immune therapies and CARMA may serve as a promising therapeutic tool for the treatment of brain metastasis.
- 2 March 2026
- Published by Springer Nature in Nature Biomedical Engineering
- p. 1-19
MyD88-mediated chimaeric antigen receptor macrophages suppress brain metastasis using target-specific phagocytosis
Metastatic brain disease occurs in up to 30% of patients with lung, melanoma and breast cancers, and the median survival time remains less than a year. Treating these patients is a challenge because surgical approaches are limited and most chemotherapeutic drugs and immunotherapies are ineffective at crossing the blood–brain barrier (BBB). Given the unique abilities of macrophages to cross the BBB and exert their phagocytic function on tumour cells, we genetically engineer macrophages that express a chimaeric antigen receptor (CAR) targeting mesothelin (MSLN). To specifically target metastatic brain tumours, we fused the cells with the immune signalling molecule MyD88. This chimaeric antigen receptor macrophage (CARMA) penetrates the BBB and decreases brain metastasis growth in a humanized mouse model. MSLN–CARMA shows antigen-specific phagocytosis activity against tumour cells and exhibits a bystander effect by releasing TNF to act on surrounding tumour cells lacking the tumour antigen. These features of CARMA represent advantages over other immune therapies and CARMA may serve as a promising therapeutic tool for the treatment of brain metastasis.
- Open Access
- 1 July 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-18
Ghrelin-induced neuronal NPY promotes brain metastasis in lung cancer patients with low BMI
Obesity is a known risk factor for many cancers, yet recent studies reveal a paradoxical association between low body mass index (BMI) and increased brain metastasis in lung cancer—referred to as the “obesity paradox,” with unclear molecular mechanism(s). Here, we show a significantly higher incidence of brain metastasis in low-BMI lung cancer patients compared to those with high-BMI or other cancer brain metastasis in a pan-analysis of 7628 patients. Mechanistically, low BMI activates ghrelin-GHSR signaling, increasing neuronal neuropeptide Y (NPY) secretion, which promotes tumor metabolic reprogramming via NPY-Y5R, facilitating brain colonization. Elevated plasma ghrelin levels in cancer-free low-BMI subjects suggest its potential as a prognostic biomarker for predicting brain metastasis. Notably, targeting NPY-Y5R or reversing low BMI effectively suppresses brain metastasis, supporting its pro-metastatic role. These findings provide a strong rationale for developing targeted interventions to treat or prevent brain metastasis in lung cancer patients with low BMI.
- 1 July 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-18
Open AccessGhrelin-induced neuronal NPY promotes brain metastasis in lung cancer patients with low BMI
Obesity is a known risk factor for many cancers, yet recent studies reveal a paradoxical association between low body mass index (BMI) and increased brain metastasis in lung cancer—referred to as the “obesity paradox,” with unclear molecular mechanism(s). Here, we show a significantly higher incidence of brain metastasis in low-BMI lung cancer patients compared to those with high-BMI or other cancer brain metastasis in a pan-analysis of 7628 patients. Mechanistically, low BMI activates ghrelin-GHSR signaling, increasing neuronal neuropeptide Y (NPY) secretion, which promotes tumor metabolic reprogramming via NPY-Y5R, facilitating brain colonization. Elevated plasma ghrelin levels in cancer-free low-BMI subjects suggest its potential as a prognostic biomarker for predicting brain metastasis. Notably, targeting NPY-Y5R or reversing low BMI effectively suppresses brain metastasis, supporting its pro-metastatic role. These findings provide a strong rationale for developing targeted interventions to treat or prevent brain metastasis in lung cancer patients with low BMI.
- RetractionOpen Access
- 22 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1
Retraction Note: Nicotine promotes breast cancer metastasis by stimulating N2 neutrophils and generating pre-metastatic niche in lung
- 22 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1
RetractionOpen AccessRetraction Note: Nicotine promotes breast cancer metastasis by stimulating N2 neutrophils and generating pre-metastatic niche in lung
- Open Access
- 14 March 2025
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 17 (4) , 797-822
MHC-I upregulation by macbecin II in the solid tumors potentiates the effect of active immunotherapy
We aimed to restore MHC-I expression on the surface of solid tumors including breast cancer and melanoma cells to regain sensitivity to immunotherapy and suppress metastatic progression. We screened a natural compound library and identified macbecin II as a reagent that upregulates MHC-I expression and induces antigen-dependent cell death in pre-invasive and invasive breast cancer models. Furthermore, we employed active immunotherapy using engineered small extracellular vesicles from dendritic cells (DCs) as a tumor vaccine (IL2-ep13nsEV) in combination with macbecin II for personalized breast cancer treatment. We found that macbecin II induced MHC-I-dependent antigen presentation and that IL2-ep13nsEV synergized with macbecin II inducing cell death, reducing metastasis, and boosting immune cell infiltration. In addition, macbecin II potentiated the effects of anti-PD-1 immunotherapy in suppressing tumor growth and metastasis. Mechanistically, macbecin II upregulated MHC-I expression post-translationally by rescuing it from lysosomal degradation. Our findings revealed a strong efficacy of macbecin II in regulating MHC-I expression and following antigen-dependent cell death. Therefore, combining active immunotherapies and macbecin II represents an effective strategy to prevent growth and progression of solid tumors including breast cancer and melanoma.
- 14 March 2025
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 17 (4) , 797-822
Open AccessMHC-I upregulation by macbecin II in the solid tumors potentiates the effect of active immunotherapy
We aimed to restore MHC-I expression on the surface of solid tumors including breast cancer and melanoma cells to regain sensitivity to immunotherapy and suppress metastatic progression. We screened a natural compound library and identified macbecin II as a reagent that upregulates MHC-I expression and induces antigen-dependent cell death in pre-invasive and invasive breast cancer models. Furthermore, we employed active immunotherapy using engineered small extracellular vesicles from dendritic cells (DCs) as a tumor vaccine (IL2-ep13nsEV) in combination with macbecin II for personalized breast cancer treatment. We found that macbecin II induced MHC-I-dependent antigen presentation and that IL2-ep13nsEV synergized with macbecin II inducing cell death, reducing metastasis, and boosting immune cell infiltration. In addition, macbecin II potentiated the effects of anti-PD-1 immunotherapy in suppressing tumor growth and metastasis. Mechanistically, macbecin II upregulated MHC-I expression post-translationally by rescuing it from lysosomal degradation. Our findings revealed a strong efficacy of macbecin II in regulating MHC-I expression and following antigen-dependent cell death. Therefore, combining active immunotherapies and macbecin II represents an effective strategy to prevent growth and progression of solid tumors including breast cancer and melanoma.
- RetractionOpen Access
- 9 January 2025
- Published by Springer Nature in Oncogene
- Vol. 44 (5) , 339
Retraction Note: Exosomal miR-4466 from nicotine-activated neutrophils promotes tumor cell stemness and metabolism in lung cancer metastasis
- 9 January 2025
- Published by Springer Nature in Oncogene
- Vol. 44 (5) , 339
RetractionOpen AccessRetraction Note: Exosomal miR-4466 from nicotine-activated neutrophils promotes tumor cell stemness and metabolism in lung cancer metastasis
- Open Access
- 11 November 2024
- Published by Springer Nature in Oncogene
- Vol. 44 (4) , 271
Correction: Regucalcin promotes dormancy of prostate cancer
- 11 November 2024
- Published by Springer Nature in Oncogene
- Vol. 44 (4) , 271
Open AccessCorrection: Regucalcin promotes dormancy of prostate cancer
- 29 November 2023
- Published by Springer Nature in Oncogene
- Vol. 43 (5) , 319-327
Functional evaluation of dendritic cells and extracellular vesicles as immunotherapy for breast cancer
Dendritic cells (DCs) play critical roles in recognizing and presenting antigens to T cells. They secrete dendritic cell-derived extracellular vesicles (DC-sEVs), which could mimic the function of DCs. Therefore, we explore the possibility of using DC-sEVs as a potential personalized vaccine in this study. We compared the efficacy of DCs and DC-sEVs on stimulating the immune system to target breast cancer cells and found that DC-sEVs had significantly more MHC molecules on the surface when compared to the parental DCs. In our in vivo and in vitro testing, Dc-sEVs showed significant advantages over DCs, regarding efficacy, safety, storage, and potential delivery advantages. DC-sEVs were able to suppress the growth of immune-cold breast tumors, while DCs failed to do so. These results indicate the strong potential utility of DC-sEVs as a personalized immunotherapy for breast cancer.
- 29 November 2023
- Published by Springer Nature in Oncogene
- Vol. 43 (5) , 319-327
Functional evaluation of dendritic cells and extracellular vesicles as immunotherapy for breast cancer
Dendritic cells (DCs) play critical roles in recognizing and presenting antigens to T cells. They secrete dendritic cell-derived extracellular vesicles (DC-sEVs), which could mimic the function of DCs. Therefore, we explore the possibility of using DC-sEVs as a potential personalized vaccine in this study. We compared the efficacy of DCs and DC-sEVs on stimulating the immune system to target breast cancer cells and found that DC-sEVs had significantly more MHC molecules on the surface when compared to the parental DCs. In our in vivo and in vitro testing, Dc-sEVs showed significant advantages over DCs, regarding efficacy, safety, storage, and potential delivery advantages. DC-sEVs were able to suppress the growth of immune-cold breast tumors, while DCs failed to do so. These results indicate the strong potential utility of DC-sEVs as a personalized immunotherapy for breast cancer.
- Open Access
- 24 October 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1298958
Editorial: Cellular and molecular characteristics of the pre-metastatic niche
Editorial: Cellular and molecular characteristics of the pre-metastatic niche
- 24 October 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1298958
Open AccessEditorial: Cellular and molecular characteristics of the pre-metastatic niche
Editorial: Cellular and molecular characteristics of the pre-metastatic niche
- Open Access
- 28 April 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (17) , eade0625
Engineering an active immunotherapy for personalized cancer treatment and prevention of recurrence
Breast cancer has been shown to be resistant to immunotherapies. To overcome this challenge, we developed an active immunotherapy for personalized treatment based on a smart nanovesicle. This is achieved by anchoring membrane-bound bioactive interleukin 2 (IL2) and enriching T cell–promoting costimulatory factors on the surface of the dendritic cell–derived small extracellular vesicles. This nanovesicle also displays major histocompatibility complex–bound antigens inherited from tumor lysate–pulsed dendritic cell. When administrated, the surface-bound IL2 is able to guide the nanovesicle to lymphoid organs and activate the IL2 receptor on lymphocytes. Furthermore, it is able to perform antigen presentation in the replacement of professional antigen-presenting cells. This nanovesicle, named IL2-ep13nsEV, induced a strong immune reaction to rescue 50% of the mice in our humanized patient-derived xenografts, sensitized cancer cells to immune checkpoint inhibitor treatment, and prevented the recurrence of resected tumors. This paradigm presents a feasible strategy for the treatment and prevention of metastatic breast cancer.
- 28 April 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (17) , eade0625
Open AccessEngineering an active immunotherapy for personalized cancer treatment and prevention of recurrence
Breast cancer has been shown to be resistant to immunotherapies. To overcome this challenge, we developed an active immunotherapy for personalized treatment based on a smart nanovesicle. This is achieved by anchoring membrane-bound bioactive interleukin 2 (IL2) and enriching T cell–promoting costimulatory factors on the surface of the dendritic cell–derived small extracellular vesicles. This nanovesicle also displays major histocompatibility complex–bound antigens inherited from tumor lysate–pulsed dendritic cell. When administrated, the surface-bound IL2 is able to guide the nanovesicle to lymphoid organs and activate the IL2 receptor on lymphocytes. Furthermore, it is able to perform antigen presentation in the replacement of professional antigen-presenting cells. This nanovesicle, named IL2-ep13nsEV, induced a strong immune reaction to rescue 50% of the mice in our humanized patient-derived xenografts, sensitized cancer cells to immune checkpoint inhibitor treatment, and prevented the recurrence of resected tumors. This paradigm presents a feasible strategy for the treatment and prevention of metastatic breast cancer.